Background Amivantamab has been approved for the treatment of patients with advanced
non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 …

PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …

Methods The dose escalation phase enrolled patients with advanced NSCLC to determine
the recommended phase 2 dose (RP2D) of 1050 mg (1400 mg for≥ 80 kg) amivantamab …

9512 Background: EGFR exon20ins-mutated NSCLC is generally refractory to EGFR
tyrosine kinase inhibitors (TKIs) and is associated with poor prognosis. Amivantamab (JNJ …

9008 Background: Amivantamab, a fully human bispecific antibody targeting epidermal
growth factor receptor (EGFR) and MET, is approved for the treatment of non-small cell lung …

Introduction EGFR exon 20 insertions comprise 4% to 9% of EGFR mutated NSCLC. Despite
being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine …

Amivantamab (amivantamab-vmjw; Rybrevant™), a bispecific monoclonal antibody
targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Background Amivantamab plus carboplatin–pemetrexed (chemotherapy) with and without
lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor …

EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer
(NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ …